Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-1596 tablets, agreeing to carry out clinical trials of this product for weight management indications and type 2 diabetes.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-1596 tablets, agreeing to carry out clinical trials of this product for weight management indications and type 2 diabetes.